Kurt Von Emster

Managing Partner at Abingworth

Kurt joined Abingworth in January 2015 bringing 25 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies Jasper, Orbus, SFJ Pharmaceuticals Tizona Therapeutics, Trishula Therapeutics, Vaxcyte and Vera Therapeutics. In addition, he is on the board of CymaBay.

Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.

Location

Menlo Park, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Abingworth

1 followers

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.


Industries

Employees

11-50

Links